Breaking News Instant updates and real-time market news.

BAC

Bank of America

$21.12

0.905 (4.48%)

, F

Ford

$11.96

0.04 (0.34%)

07:35
12/01/16
12/01
07:35
12/01/16
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Wednesday in Bank of America (BAC), Ford (F), Home Depot (HD), Whiting Petroleum (WLL), Visa (V), Deere (DE), Teva (TEVA), Nabors Industries (NBR), Skechers (SKX), and TD Ameritrade (AMTD).

BAC

Bank of America

$21.12

0.905 (4.48%)

F

Ford

$11.96

0.04 (0.34%)

HD

Home Depot

$129.40

-0.22 (-0.17%)

WLL

Whiting Petroleum

$12.22

2.84 (30.28%)

V

Visa

$77.32

-1.83 (-2.31%)

DE

Deere

$100.20

-0.15 (-0.15%)

TEVA

Teva

$37.41

-0.16 (-0.43%)

NBR

Nabors Industries

$16.10

2.93 (22.25%)

SKX

Skechers

$22.78

1.3 (6.05%)

AMTD

TD Ameritrade

$41.01

0.38 (0.94%)

  • 01

    Dec

  • 10

    Jan

  • 13

    Jan

  • 03

    Apr

BAC Bank of America
$21.12

0.905 (4.48%)

11/16/16
11/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sysco (SYY) downgraded to Neutral from Outperform at Credit Suisse with analyst Edward Kelly saying Sysco shares are up 50% over the last 18 months and now views risk/reward as balanced. 2. Teva (TEVA) downgraded to Hold from Buy at Jefferies, to Equal Weight from Overweight at Morgan Stanley, and to Neutral from Buy at BTIG. 3. Bank of America (BAC) Capital One (COF) downgraded to Neutral from Outperform at Baird while the firm downgraded Fifth Third (FITB) to Underperform from Neutral. 4. Zions Bancorp (ZION) downgraded to Equal Weight from Overweight at Morgan Stanley and to Market Perform from Outperform at Bernstein. 5. Yingli Green Energy (YGE) downgraded to Sell from Buy at Axiom while the firm downgraded SolarCity (SCTY) and JA Solar (JASO) to Sell from Hold. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/16
11/16/16
DOWNGRADE
Target $18

Neutral
Bank of America downgraded to Neutral from Outperform at Baird
As previously reported, Baird analyst David George downgraded Bank of America to Neutral from Buy as he believes the post-election rally has largely discounted the potential benefits of rising interest rates, lower taxes, and more aggressive capital return. George raised his price target to $18 from $17 on Bank of America shares.
11/29/16
KBWI
11/29/16
UPGRADE
Target $23
KBWI
Outperform
Bank of America upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Bank of America to Outperform citing expectations for improved operating and regulatory environments. The valuation remains reasonable despite the recent rally, Kleinhanzl tells investors in a research note. The analyst raised his price target for the shares to $23 from $17.50.
11/16/16
BARD
11/16/16
DOWNGRADE
BARD
Neutral
Bank of America downgraded to Neutral from Outperform at Baird
F Ford
$11.96

0.04 (0.34%)

11/30/16
MACQ
11/30/16
INITIATION
Target $13
MACQ
Neutral
Ford initiated with a Neutral at Macquarie
Macquaire analyst Takuo Katayama initiated Ford with a Neutral and a $13 price target saying the company lacks catalysts over the near-term and its new product flow is underwhelming and expects it to remain that way until late 2018.
10/31/16
DAIW
10/31/16
UPGRADE
DAIW
Hold
Ford upgraded to Neutral from Underperform at Daiwa
10/31/16
10/31/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Neutral from Underperform at Daiwa. 2. Chevron (CVX) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying that after a decade of relatively flat production, the company is positioned for "strong volume improvement." 3. Fossil (FOSL) upgraded to Mixed from Negative at OTR Global with the firm saying checks indicate the response to Michael Kors (KORS) watches has been strong. 4. ADTRAN (ADTN) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux citing the share pullback over merger concerns of its top customer CenturyLink (CTL). 5. Deere (DE) upgraded to Outperform from Neutral at Baird with analyst Mircea Dobre saying that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/16
BREN
11/22/16
INITIATION
Target $10
BREN
Sell
Ford initiated with a Sell at Berenberg
Target $10.
HD Home Depot
$129.40

-0.22 (-0.17%)

11/16/16
UBSW
11/16/16
NO CHANGE
Target $145
UBSW
Buy
Home Depot earnings support upside from current levels, says UBS
UBS analyst Michael Lasser believes the market reaction surrounding Home Depot's Q3 results were short-sighted. He said the company's comps provided evidence it can sustain momentum for a while. Lasser sees the company's strong earnings growth as supporting upside from current levels and reiterated his Buy rating and $145 price target on Home Depot shares.
11/16/16
OPCO
11/16/16
NO CHANGE
Target $80
OPCO
Outperform
'Messy' third quarter from Lowe's, says Oppenheimer
Oppenheimer analyst Brian Nagel looks upon the weaker than expected Q3 results and modestly more subdued 2016 guidance that Lowe's (LOW) reported today as not totally shocking, but disappointing nonetheless. The analyst points out that the tone of Lowe's press release implies that management may be embarking upon some type of "reset." Further, Nagel says Lowe's took a number of charges in Q3 and seems set to invest differently going forward. The analyst continues to view Home Depot (HD) as the better play in home improvement retail. He reiterates an Outperform rating and $80 price target on Lowe's shares.
11/15/16
BARD
11/15/16
NO CHANGE
Target $150
BARD
Outperform
Home Depot report reinforces positive view, supports Lowe's estimate, says Baird
Baird analyst Peter Benedict said the "solid" Q3 report and "potentially conservative" outlook from Home Depot (HD) reinforces his positive view of the stock and also supports his 2.5% U.S. comp growth estimate for peer Lowe's (LOW), which is scheduled to report before the market open tomorrow. Benedict has an Outperform rating and $150 price target on Home Depot shares.
11/01/16
OPCO
11/01/16
NO CHANGE
Target $80
OPCO
Outperform
Lowe's price target lowered to $80 from $94 at Oppenheimer
Oppenheimer analyst Brian Nagel lowered his price target for Lowe's (LOW) to $80 from $94 on valuation. The analyst notes that "softish reports" from Home Improvement related manufacturers and suppliers have sparked investor concern that a weaker spending environment has finally caught up with the company and Home Depot (HD). However, Nagel believes any sales weakness that occurred late summer is more of a "blip" than the beginning of a "sales downshift" for the sector, and recommends clients use recent share price weakness as a buying opportunity. He reiterates an Outperform rating on Lowe's shares. Nagel also lowered his price target for Home Depot.
WLL Whiting Petroleum
$12.22

2.84 (30.28%)

10/28/16
SPHN
10/28/16
UPGRADE
SPHN
Overweight
Whiting Petroleum upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Will Green upgraded Whiting Petroleum to Overweight from Equal Weight, saying that the "worst may be behind" for the company.
10/10/16
RHCO
10/10/16
NO CHANGE
RHCO
Whiting Petroleum named top pick at SunTrust
SunTrust analyst Neal Dingmann named Whiting Petroleum as his top pick. The analyst says that recent developments at the company should enable its production to remain "at least flat," while the company should get a big boost from recent oil price rises.
12/01/16
STFL
12/01/16
UPGRADE
Target $15
STFL
Buy
Whiting Petroleum upgraded to Buy from Hold at Stifel
Stifel analyst Michael Scialla upgraded Whiting Petroleum to Buy with a $15 price target. The OPEC agreement to cut production resulted in Stifel raising its 2017 oil price forecast to $55/bbl from $50bbl. Scialla had been concerned about Whiting's above average debt/TTM EBITDA prior to the announcement but now sees reduced risk and strong long-term growth.
10/28/16
RAJA
10/28/16
UPGRADE
Target $16
RAJA
Strong Buy
Whiting Petroleum upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst John Freeman upgraded Whiting Petroleum to Strong Buy and raised its price target to $16 from $14. The analyst said Whiting reported "extremely impressive" Q3 report and now plans to double its Bakken rig count and sees double-digit production growth from current levels in 2017.
V Visa
$77.32

-1.83 (-2.31%)

11/22/16
JEFF
11/22/16
NO CHANGE
JEFF
Buy
Visa pullback on new U.S. debit routing policies an overreaction, says Jefferies
Jefferies analyst Jason Kupferberg said he views the pullback in Visa shares following the company's new U.S. debit routing policies as an overreaction and recommends buying amid today's weakness. Visa could lose some U.S. PIN debit market share, but even in a worst-case scenario the analyst doesn't see any more than a "very low single-digit" EPS impact, he tells investors.
10/25/16
10/25/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. T-Mobile (TMUS) downgraded to Buy from Conviction Buy at Goldman with analyst Brett Feldman citing recent share outperformance. 2. Under Armour (UA) downgraded to Market Perform from Outperform at William Blair with analyst Sharon Zackfia saying the company's investments will constrain earnings growth to the mid-teens through 2018. 3. Visa (V) downgraded to Neutral from Buy at Guggenheim. 4. Sonic (SONC) downgraded to Market Perform from Outperform at Telsey Advisory and to Equal Weight from Overweight at Stephens. 5. VF Corp. downgraded to Neutral from Overweight at JPMorgan, to Neutral from Buy at Citi, and to Hold from Buy at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/16
DBAB
10/25/16
NO CHANGE
Target $103
DBAB
Buy
Visa FY17 guidance looks conservative, says Deutsche Bank
Deutsche Bank analyst Bryan Keane says Visa reported a "solid beat" for Q4 and that its outlook for FY17 appears conservative. The analyst keeps a Buy rating on the shares with a $103 price target.
11/15/16
JEFF
11/15/16
NO CHANGE
JEFF
Jefferies sees attractive entry points for Payments stocks
Payments stocks Visa (V), MasterCard (MA), PayPal (PYPL), Global Payments (GPN), Vantiv (VNTV) have been big underperformers since Election Day as investors rotate into core Financials, Jefferies analyst Jason Kupferberg tells investors in a research note. The corrections of up to 10% are not warranted fundamentally, the analyst contends. Kupferberg sees attractive entry points at current levels and highlights PayPal and Visa as his top picks.
DE Deere
$100.20

-0.15 (-0.15%)

12/01/16
12/01/16
UPGRADE
Target $124

Buy
Deere upgraded to Buy, guidance seems conservative, says BofA/Merrill
As previously reported, BofA/Merrill upgraded Deere (DE) Buy from Neutral and raised its price target to $124 from $92 Analyst Ross Gilardi believes Deere's FY17 guidance is conservative and his revised earnings estimate of $4.60 is 7% above consensus. Gilardi said Deere trades at a steep discount to Caterpillar (CAT), North American ag demand is at a 20-year lows, C&F is a potential US fiscal stimulus beneficiary and margins should only get better, and corn and oil prices are directionally correlated.
11/28/16
BMOC
11/28/16
NO CHANGE
BMOC
Deere price target raised to $120 from $96 at BMO Capital
BMO Capital analyst Joel Tiss raised his price target on Deere after the company reported stronger than expected Q4 results. The analyst says that the company's outlook has improved significantly, and he notes that it said that agricultural markets have bottomed. Tiss keeps an Outperform rating on the shares.
11/28/16
11/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deere (DE) upgraded to Neutral from Underweight at Piper Jaffray with analyst Brett Wong saying investors will likely continue to pay "lofty multiples" since a bottom of the cycle is close. 2. ConocoPhillips (COP) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying ConocoPhillips offers the most attractive free cash yield among U.S. majors/E&P and believes the company will grow its production through the ned of the decade. 3. Comerica (CMA) upgraded to Buy from Hold at Jefferies with analyst Ken Usdin saying the company's earnings are likely to benefit more than peers from higher short-term interest rates and a potentially lower Federal tax rate. 4. DuPont Fabros (DFT) upgraded to Outperform from Neutral at Baird with analyst David Rodgers citing its future development opportunity, solid corporate execution, and valuation. 5. Horizon Pharma (HZNP) upgraded to Buy from Neutral at Citi analyst Liav Abraham saying the risk/reward as favorable into the upcoming pivotal data for Actimmune in Friederich's Ataxia. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/01/16
BOFA
12/01/16
UPGRADE
BOFA
Buy
Deere upgraded to Buy from Neutral at BofA/Merrill
TEVA Teva
$37.41

-0.16 (-0.43%)

11/25/16
PIPR
11/25/16
NO CHANGE
Target $47
PIPR
Overweight
Alder recent selloff an overreaction, says Piper Jaffray
Piper Jaffray analyst Charles Duncan attributes the recent weakness in shares of Alder Biopharmaceuticals (ALDR) to "increased visibility and outcome uncertainty" for the company's challenge to Teva's (TEVA) anti-CGRP patents in the U.S. and Europe. The analyst views the selloff as an overreaction and remains focused on his "clinical data-driven thesis for the emerging, differentiated profile of lead candidate ALD403." Duncan keeps an Overweight rating on Alder with a $47 price target.
11/17/16
MAXM
11/17/16
NO CHANGE
Target $52
MAXM
Buy
Teva price target lowered to $52 from $72 at Maxim
Maxim analyst Gabrielle Zhou lowered her price target for Teva to $52 from $72 after the company reported Q3 results and cut it full-year guidance. The analyst notes that the company has started its Actavis integration, with the latter now contributing to Teva's generic revenues. However, she believes Teva needs to focus now on growth, noting that 2017 will be a challenge. Zhou reiterates a Buy rating on Teva's shares.
11/22/16
LEER
11/22/16
NO CHANGE
LEER
Outperform
Alder Biopharmaceuticals patent fight far from over, says Leerink
Leerink analyst Joseph Schwartz says Alder Biopharmaceuticals (ALDR) stated that the European Patent Office issued a ruling revoking all claims in its competitor Teva's (TEVA) patent relating to CGRP antagonist antibodies but maintaining and narrowing claims relating to the use of CGRP antagonist antibodies in human therapy to the prevention or treatment of headache such as migraine and cluster headache. The analyst notes that the persistence of the headache claims has concerned investors, but points out that Alder believes the patent fight is far from over in the EU, or moreover in the U.S. Schwartz reiterates an Outperform rating on Alder's shares.
NBR Nabors Industries
$16.10

2.93 (22.25%)

11/21/16
GSCO
11/21/16
UPGRADE
Target $18
GSCO
Conviction Buy
Nabors Industries upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Waqar Syed added Nabors to the Conviction Buy List and raised its price target to $18 from $16.50 following an increase in 1H 2017 WTI forecast to $55/bbl. The firm said Nabors offers cyclical upside from increased activity, earnings power, and attractive valuation.
10/28/16
UBSW
10/28/16
NO CHANGE
Target $17
UBSW
Buy
Nabors Industries price target raised to $17 from $12 at UBS
UBS analyst Angie Sedita raised her price target on Nabors Industries to $17 from $12 following the company's analyst day. The analyst believes the overall story remains on track as the company is gaining market share and there is modest pricing traction for high-spec rigs. Sedita also cited the company's new initiatives and its valuation being at a "sharp discount" to its peers, which she feels is unwarranted. Sedita reiterated her Buy rating on Nabors shares.
10/19/16
GSCO
10/19/16
NO CHANGE
Target $16.5
GSCO
Buy
Goldman says to buy Nabors Industries for earnings and beyond
Goldman analyst Waqar Syed said Nabors will not only benefit from the recent pick-up in US land rig activity, but also offers an above-market growth opportunity from the expansion of ancillary services offered on its rigs. Nabors is targeting $250M in EBITDA from these services in 2-3 years from almost zero today, and should provide further color at its November 10 investor day. Syed expects revenue/margin momentum in Q3 to carry into Q4, given that the current US land rig count is 12% above the Q3 average, and continues to move higher, and recommends buying Nabors for earnings and beyond. The analyst rates Nabors a Buy and increased his price target to $16.50 from $11.50.
11/29/16
TUDR
11/29/16
UPGRADE
TUDR
Buy
Nabors Industries upgraded to Buy from Hold at Tudor Pickering
SKX Skechers
$22.78

1.3 (6.05%)

11/03/16
RILY
11/03/16
DOWNGRADE
Target $24
RILY
Neutral
Skechers downgraded to Neutral at B. Riley
As previously reported, B. Riley analyst Jeff Van Sinderen downgraded Skechers to Neutral from Buy, saying his most recent checks only raise his level of concern and he has trouble seeing a catalyst for business reacceleration. The analyst keeps a $24 price target on Skechers shares.
11/03/16
RILY
11/03/16
DOWNGRADE
RILY
Neutral
Skechers downgraded to Neutral from Buy at B. Riley
11/02/16
WEDB
11/02/16
INITIATION
Target $23
WEDB
Neutral
Skechers initiated with a Neutral at Wedbush
Wedbush analyst Christopher Svezia initiated Skechers with a Neutral and a $23 price target.
12/01/16
BUCK
12/01/16
UPGRADE
Target $31
BUCK
Buy
Skechers upgraded to Buy from Neutral at Buckingham
Buckingham analyst Scott Krasik upgraded Skechers to Buy and raised its price target to $31 from $21 after viewing new products at the FFANY tradeshow. The analyst believes Skechers is one quarter away from a sales inflections driven by a new product cycle and notes reduced inventory after Q2 reduces the risk of another major negative earnings revision near-term. Further, Krasik said Chairman and CEO Robert Greenberg purchased $11M of stock this week, his first purchase in 15 years.
AMTD TD Ameritrade
$41.01

0.38 (0.94%)

10/13/16
BOFA
10/13/16
UPGRADE
Target $43
BOFA
Buy
TD Ameritrade upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded TD Ameritrade (AMTD) to Buy and raised its price target to $43 from $33. The analyst sees upside from higher interest rates given TD Ameritrade's exposure to the curve and from other strategic factors including M&A activity and/or competitive/pricing. Carrier said M&A speculation in the space is picking up and said its plausible for TD Ameritrade to acquire privately held Scottrade and/or E-Trade (ETFC).
10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/16
DBAB
10/25/16
NO CHANGE
Target $33
DBAB
Buy
E-Trade, Ameritrade deal less likely over next year, says Deutsche Bank
Deutsche Bank analyst Brian Bedell believes TD Ameritrade's (AMTD) acquisition of Scottrade makes an E-Trade (ETFC)/Ameritrade deal "much less likely" for at least 12-18 months. The analyst expects pricing competition to rise as e-brokers look to attract Scottrade and Ameritrade customers via various discounts. Bedell views Charles Schwab (SCHW) as the best positioned in this environment. The analyst has Buy ratings on Schwab and E-Trade and a Hold rating on TD Ameritrade.
09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.

TODAY'S FREE FLY STORIES

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.